I have read many of Chris Kallos's MST research reports over the years , and he's always been level headed and pragmatic in his reviews ...
.... but , lest we lose sight of the main issue here : Improving health outcomes for patients .... CYP has achieved a very positive result in a trial to improve the healing of diabetics with foot ulcer wounds ... this is an extremely awesome thing for those folks who are suffering ... which also includes us long time shareholders ...
Ann: Encouraging Initial Data from CYP-006TK DFU Trial, page-50
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $10.82K | 65.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4450 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 88474 | 2 |
View Market Depth
| Last trade - 15.32pm 20/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |